SCHEMBL8245259

SCHEMBL8245259

Nc1ccccc1NC(=O)Cc1csc(NC(=O)OCc2nc3ccccc3s2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.46
CYP1A2 P05177 2/20 0.45
CYP2C19 P33261 2/20 0.45
SMN1; SMN2 Q16637 7/20 0.45
KDM4E B2RXH2 1/20 0.45
MAPT P10636 6/20 0.44
TSHR P16473 2/20 0.44
HSD17B10 Q99714 2/20 0.44
PKM P14618 1/20 0.44
HTT P42858 1/20 0.44
ALOX15 P16050 1/20 0.44
MEN1 O00255 3/20 0.43
ALDH1A1 P00352 3/20 0.43
ALOX12 P18054 3/20 0.43
KMT2A Q03164 3/20 0.43
LMNA P02545 2/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
HDAC3 O15379 2/20 0.42
HDAC1 Q13547 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8248453 0.87 PDE5A (0.54) CYP1A2CYP2C19SMN1; SMN2KDM4EMAPT
SCHEMBL8247957 0.83 GAA (0.48) GAACYP1A2CYP2C19SMN1; SMN2KDM4E
SCHEMBL8246351 0.81 GAA (0.49) GAACYP1A2CYP2C19SMN1; SMN2KDM4E
SCHEMBL8245740 0.81 HDAC3 (0.49) GAACYP1A2CYP2C19SMN1; SMN2KDM4E
SCHEMBL13316917 0.80 PDE5A (0.46) CYP1A2CYP2C19SMN1; SMN2KDM4EMAPT
SCHEMBL13316919 0.80 PDE5A (0.48) CYP1A2CYP2C19SMN1; SMN2KDM4EMAPT
SCHEMBL13316916 0.79 PDE5A (0.49) CYP1A2CYP2C19SMN1; SMN2KDM4EMAPT
SCHEMBL8246412 0.79 HDAC3 (0.54) GAASMN1; SMN2KDM4EMAPTHTT
SCHEMBL3597144 0.77 SMN1; SMN2 (0.57) GAACYP1A2CYP2C19SMN1; SMN2KDM4E
SCHEMBL3607165 0.76 PKM (0.42) GAASMN1; SMN2KDM4EMAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100152188-A1 Novel Heterocyclic Compounds ORCHID RESEARCH LABORATORIES LIMITED (IN) 2010-06-17 US disclosed
US-20100152188-A1 Novel Heterocyclic Compounds ORCHID RESEARCH LABORATORIES LIMITED (IN) 2010-06-17 US disclosed
WO-2007017728-A2 NOVEL HETEROCYCLIC COMPOUNDS ORCHID RESEARCH LABORATORIES LIMITED (IN) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152188-A1 Novel Heterocyclic Compounds CYP11B2, CYP3A5, CYP11B1 GAA 325/4885CYP1A2 16/4885CYP2C19 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.